BiotechTube
Galactica Pharmaceuticals

Galactica Pharmaceuticals

Boston, United States· Est.
galacticapharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Galactica Pharmaceuticals is a private, preclinical biotech founded in 2020 (with roots dating to 2005) and based in Boston, USA. Its core asset is a proprietary RAGE-Fc fusion protein, which has shown promising preclinical efficacy in COVID-19, diabetic complications, and macular degeneration, positioning it as a potential multi-indication therapeutic. The company is 'IND-ready' and plans to file its first IND within 15-18 months, with a potential accelerated path for COVID-19, while operating under a capital-efficient virtual model.

Infectious DiseaseMetabolic DisordersOphthalmologyAutoimmune/InflammatoryNeurology

Technology Platform

Proprietary RAGE-Fc fusion protein acting as a soluble decoy receptor to neutralize DAMPs/AGEs and inhibit pathological inflammation.

Opportunities

The RAGE-Fc protein addresses massive, costly markets with high unmet need, particularly in diabetic complications and dry AMD where no effective therapy exists.
Its subcutaneous administration offers a key competitive advantage over intraocular injections in ophthalmology.
The single molecule's potential across multiple indications creates significant value through pipeline-in-a-product efficiency.

Risk Factors

The company faces high translational risk as all data is preclinical, and its entire value depends on a single asset.
Operating as a virtual company introduces execution and coordination risks with external partners.
Significant financing will be required to advance into costly clinical trials, creating substantial funding risk.

Competitive Landscape

In diabetic complications, Galactica would compete against standard-of-care management and newer targeted therapies. In wet AMD, it faces entrenched competition from anti-VEGF drugs like Eylea and Lucentis, requiring demonstration of non-inferiority and superior convenience. For dry AMD, it would be a first-mover in a vast, untreated market, but several other mechanisms are also in clinical development.

More companies in Small Molecule Drugs →More companies in United States →